|Bid||71.45 x 800|
|Ask||72.45 x 900|
|Day's Range||71.00 - 73.60|
|52 Week Range||3.65 - 74.75|
|Beta (3Y Monthly)||-0.12|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 24, 2018 - Oct 29, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||69.33|
"We did like it when it was at $140, $150 -- but what's happened is that it's just literally up 40 straight points [since then]," Cramer said during an exclusive video-conference call for members of his Action Alert PLUS club for investors. Cramer, whose charitable trust already owns AAPL, recommended against putting new money into the stock despite recent upgrades or positive comments about the stock from Bank of America, Morgan Stanley and Cowen. Cramer said Apple should buy Tandem and Dexcom, whose systems can display your blood-glucose levels on an Apple Watch or iPhone.
Tandem Diabetes' (TNDM) insulin pump seems to be a strategic fit and well-timed from its massive uptake by the diabetic patients in Canada.
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that it is now registered as an approved vendor of insulin pumps and supplies under the Assistive Devices Program (ADP) in Ontario, Canada. “This registration is meaningful, as approximately 40 percent of people living with type 1 diabetes in Canada reside in Ontario and are now able to obtain reimbursement for the t:slim X2 insulin pump,” said John Sheridan, president and CEO of Tandem Diabetes Care.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today announced that John Sheridan, president and chief executive officer, wi
Tandem Diabetes Care, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced that it intends to use its remote software update tool, the Tandem Device Updater, to resolve a Control-IQ technology software anomaly identified during the ongoing DCLP3 phase of the International Diabetes Closed Loop (IDCL) clinical trial. The Company anticipates that the software update will be available to study sites before the end of March.
Blickenstaff added that Tandem has taken a consumer electronics approach to diabetes management, making sleek, stylish products. The latest technology and algorithms do most of the work managing insulin, leaving the patient to mostly just monitor the results.
NEW YORK, March 01, 2019 -- In new independent research reports released early this morning, Capital Review released its latest key findings for all current investors, traders,.
Tandem Diabetes Care (NASDAQ:TNDM) shot higher after surpassing earnings and revenue estimates. TNDM stock ended its string of losses and announced that COO John Sheridan would assume the CEO position on March 1. Current CEO Kim Blickenstaff will become Executive Chairman.Source: Tandem Diabetes However, this places Tandem Diabetes Care stock in an awkward position. The monopoly power that comes with its latest pump should ensure revenue growth for years to come.However, an unprecedented run from penny-stock status to just above $62 per share over the last year makes a near-term pullback more likely. The move higher over the previous year means TNDM stock belongs on watch lists. However, I would wait for a pullback before putting it in a portfolio.InvestorPlace - Stock Market News, Stock Advice & Trading Tips * 9 Best Stocks to Buy on U.S.-China Trade Optimism The NumbersTNDM stock rose by more than 27% in morning trading following its earnings beat and surprise profit. The San Diego-based firm reported a profit in the fourth quarter of $3.7 million, or two cents per share. Analysts had expected a loss of 20 cents per share.Quarterly revenue also significantly surpassed estimates, coming in at $76.2 million. This represents an 89.1% increase from year-over-year levels when the company reported revenues of $40 million. Wall Street had previously predicted $56.34 million for the quarter. A 133% increase in the sales of pumps bolstered this increase.Results for the full-year yielded similar positive surprises. TNDM reported revenues of $183.9 million, a 71% increase over the $107.6 million reported in 2017. However, net losses came in much higher for the year. In 2018, the company lost $122.6 million. Still, that factors in a $66.5 million non-cash charge and a $5.3 million loan repayment.The company also guided higher for 2019. The company predicts it will bring in between $225 million and $270 million in revenue. Analysts had previously forecasted $219.48 million. Although they declined to predict earnings, they do forecast that adjusted EBITDA will break even. Analysts forecast a 75-cent per share loss for fiscal 2019. TNDM Stock Has Gone to ExtremesThese improving prospects cap off a wild run for TNDM stock over the last five years. TNDM had fallen from a peak of over $300 per share in early 2014 to just over $2 per share by the fall of 2017. In 2016, TNDM stock tanked as United Health (NYSE:UNH) chose Medtronic (NYSE:MDT) insulin products over its own. Mounting losses and cash concerns weighed on the stock over the next two years.However, the outlook for the company improved last year when the FDA approved a system which combines Tandem's pump with a glucose monitor made by DexCom (NASDAQ:DXCM). This patent-protected solution helps protect people with Type-1 diabetes from dangerous highs and lows in insulin levels. It also gives Tandem a product monopoly that has caused an unprecedented rise in TNDM stock. Today's surge takes Tandem from penny-stock levels to over $59 per share in the last year alone. The TNDM Stock ConundrumStill, the very factors that have lifted TNDM stock have also made buying the equity difficult. The stock rose by 1,509% in 2018. The post-earnings bump means the increase so far in 2019 comes close to 65%. Without question, the future looks promising. It remains a question of how promising.Even before the company issued higher guidance, TNDM traded at more than 12 times sales. Moreover, despite the quarterly profit, analysts expect annual losses through 2021.I think TNDM will become profitable in time. I also believe the stock will continue to rise in the long run. However, in the near-term, this has come too far too fast. I would not discourage those who want TNDM stock from buying in at some point. Still, I would wait for a pullback. The Bottom Line on TNDM StockThe factors driving the long-term success of Tandem Diabetes Care stock have placed TNDM stock in an uncertain position for now. TNDM soared higher in morning trading as the company beat revenue and earnings estimate. Higher guidance and changes at the top level also bolstered the stock.I see TNDM stock as a lucrative long-term opportunity. The monopoly power coming from its latest pump will bring continued revenue growth. Moreover, placing John Sheridan in the CEO position and moving Kim Blickenstaff to the board of directors engenders stability amid the personnel changes.However, investors need to remember that TNDM stock has grown from penny-stock levels to more than $62 per share over the last year. With an elevated price-to-sales ratio and annual profits still out of reach, a near-term pullback remains a distinct possibility.The company's monopoly ensures Tandem will become one of the more essential medical equipment companies. As a result, TNDM stock will trade at higher levels years from now. However, with the near-term picture more uncertain, I do not see now as the time to buy.As of this writing, Will Healy did not hold a position in any of the aforementioned stocks. You can follow Will on Twitter at @HealyWriting. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 5 STARS Stocks That Continue to Define the Future * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio * 5 Real Estate Stocks to Buy for Dividend Income Compare Brokers The post Wait for the Inevitable Pullback to Buy TNDM Stock appeared first on InvestorPlace.
Chemed (CHE) sees revenue growth across its wholly-owned subsidiaries, VITAS Healthcare and Roto-Rooter. Its capital deployment policy is based on buyouts and solid return of cash to shareholders.
The roll-out of t:slim X2 with Basal-IQ technology, increased supply capacity and renewal sales, as well as the international launch, drive Tandem's (TNDM) Q4 revenues.
Shares of Tandem Diabetes Care Inc. soared in Tuesday's extended session after the medical device company named a new chief executive and posted better-than-expected quarterly results. Tandem said it named John Sheridan as new chief executive officer to succeed Kim Blickenstaff, who will become the new executive chairman of the board, effective March 1. The company also reported it swung to fourth-quarter earnings of $3.7 million, or 2 cents a share, from a loss of $11.4 million, or $1.23 a share, a year ago. Revenue rose to $76.2 million versus $40.3 million on the back of a 133% increase in pump shipments to 16,168 units. Analysts surveyed by FactSet had forecast a loss of 20 cents a share on revenue of $56.4 million. For 2019, the company expects sales in a range of $225 million to $270 million. Tandem Diabetes shares rallied 16% after hours.
Tandem Diabetes Care®, Inc. (TNDM), a leading insulin delivery and diabetes technology company, today announced a succession plan for its chief executive officer (CEO) and select members of its board of directors. John F. Sheridan will succeed Mr. Blickenstaff, assuming the role of President and CEO effective March 1, 2019.
Tandem Diabetes Care, Inc. , a leading insulin delivery and diabetes technology company, today reported its financial results for the quarter and year ended December 31, 2018 and financial guidance for the year ending December 31, 2019.
NEW YORK, NY / ACCESSWIRE / February 26, 2019 / Revance Therapeutics, Inc. (NASDAQ: RVNC ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on February 26, 2019 ...